Navigation Links
Data From Clinical Study of bioTheranostics Molecular Diagnostic Test Presented at American Society of Clinical Oncology Annual Meeting
Date:6/1/2009

- THEROS CancerTYPE ID(R) predicts cancer origin with 75 percent accuracy in patients whose primary cancer was 'unknown' using traditional diagnostics -

SAN DIEGO, June 1 /PRNewswire/ -- bioTheranostics, a bioMerieux company that discovers, develops and commercializes new molecular diagnostic tests in oncology, announced that a recent study demonstrated the company's THEROS CancerTYPE ID(R) molecular diagnostic test predicted cancer origin with 75 percent accuracy in patients whose primary cancer was initially "unknown" using traditional diagnostics. Findings were presented today at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Fl.

Three to five percent of all cancer patients(1) (the equivalent of 45,000-75,000 new patients each year in the United States alone) receive a diagnosis of cancer of unknown primary origin, or CUP, meaning their cancer has spread to multiple locations and the site where the cancer started can not be determined. Given that the origin of a cancer significantly impacts physicians' therapeutic decisions as well as patients' prognoses, the inability to diagnose patients' primary cancers makes it more difficult for physicians to determine optimal treatment plans. Molecular diagnostic tests such as the THEROS CancerTYPE ID have demonstrated the ability to predict the origin of tumors with a higher success rate than traditional diagnostic tests, thereby helping to reduce the number of cancers that remain "unknown".

The blinded study involved 28 patients who had an unknown primary cancer that was subsequently identified during their lives. Researchers assessed tissue from these patients' initial biopsies, determining that 20 of them were appropriate for testing with the THEROS CancerTYPE ID (eight were excluded given insufficient tumor tissue or poorly preserved RNA). Without accessing other clinical or pathological data for these patients, the team then compared the THEROS CancerTYPE ID cancer type predictions to the actual primary sites previously identified for each patient.

Among the 20 samples that were appropriate for testing, 15 site-of-origin predictions (75 percent) provided by the THEROS CancerTYPE ID test were accurate based on the actual clinical diagnoses. In contrast, traditional diagnostic methods often fail to properly diagnose unknown cancers even after extensive work-up that could cost up to $18,000.(2)

"Cancers of unknown primary origin present unique and significant challenges to both medical professionals and patients," said Richard Ding, bioTheransotics chief executive officer. "As the clinical validity and utility of molecular diagnostic tests such as the THEROS CancerTYPE ID continue to be demonstrated in clinical studies, we are eager to work with the oncology and pathology communities to integrate molecular diagnostic tools into routine cancer diagnosis."

The abstract, "Unknown Primary Cancer (UPC): Accuracy of Tissue of Origin Prediction by Molecular Profiling" is available online at the ASCO Web site, www.abstract.asco.org.

About bioTheranostics

bioTheranostics discovers, develops and commercializes molecular diagnostic tests for cancer patients. Leveraging its unique expertise in genomic profiling and proprietary algorithms, bioTheranostics provides innovative tests to the oncology community that help drive personalized treatment. The company operates a CLIA-certified, CAP-accredited diagnostic service laboratory in San Diego, CA to perform its proprietary molecular diagnostic tests: THEROS CancerTYPE ID(R), a molecular cancer classifier particularly helpful for patients diagnosed with primary or metastatic cancer where the origin is uncertain or unknown; and the THEROS Breast Cancer Index(SM), a combination of THEROS H/I(SM) (HOXB13:IL17BR) and THEROS MGI(SM) (Molecular Grade Index) that refines and improves risk stratification in patients with estrogen receptor (ER)-positive, lymph-node negative breast cancer. More information is available at www.bioTheranostics.com.

(1) N. Pavlidis, E. Briasoulis, J. Hainsworth, F.A. Greco. Diagnostic and therapeutic management of cancer of an unknown primary. Euro J of Cancer. 2003; 39:1990-2005.

(2) D. V. Schapira and A. R. Jarrett. The need to consider survival, outcome, and expense when evaluating and treating patients with unknown primary carcinoma. Arch Int Med. 1995; 155.

    Contact:  Michele Parisi
              925/429-1850
              mparisi@biocommnetwork.com


'/>"/>
SOURCE bioTheranostics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... Iowa , June 6, 2017  Diplomat Specialty Infusion Group, ... sterile compounding environment to its Iowa location. ... Urbandale now features an ISO 7 cleanroom—the standard ... controlled environment with a low level of pollutants. ... more IV nutrition consumers and better serve our Iowa ...
(Date:6/2/2017)... Mass. , June 2, 2017  NxStage Medical, ... renal care, today announced new findings demonstrating positive biochemical ... ® System One™. The data will be presented ... in Madrid, Spain . ... to Improve Home Dialysis Network in Europe ...
(Date:5/30/2017)... , May 30, 2017 Therapix Biosciences Ltd. ... specializing in the development of cannabinoid-based drugs, today ... company overview at three upcoming scientific and investor ... LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology:
(Date:6/27/2017)... ... June 27, 2017 , ... Children’s National Health System received top ... its Neonatology program ranking #1 out of more than 1500 neonatal intensive care ... coveted Honor Roll, a distinction given to the top performing children’s hospitals in the ...
(Date:6/26/2017)... ... 26, 2017 , ... Antoine Dental Center is now offering various types of dental ... act as a support for prosthetic teeth, such as crowns, bridges, or dentures. An implant ... a sturdy, lasting new root for the tooth. , Several types of dental implants ...
(Date:6/26/2017)... (PRWEB) , ... June 26, 2017 , ... ... group in the country, today announced the hiring of Richard Robinson as chief ... diverse leadership and operations experience, with a proven track record of simplifying business ...
(Date:6/26/2017)... (PRWEB) , ... June 26, 2017 , ... ... and urinary leakage is revolutionizing the way women look and feel about themselves ... the problem of female sexual dysfunction and urinary leakage head on with a ...
(Date:6/26/2017)... ... June 26, 2017 , ... If the ... seeing lots of red these days. According to recent estimates, 75 – 80% ... medical coding errors(1). Some studies point to Electronic Health Records (EHR) with automated ...
Breaking Medicine News(10 mins):